Abbvie, US reach agreement to cut drug prices

Core Viewpoint - Abbvie has entered into a three-year agreement with the U.S. government to offer lower prices in Medicaid through the TrumpRx initiative, while committing $100 billion over the next decade for research and development [1] Group 1 - Abbvie's agreement with the Trump administration aims to provide low prices for Medicaid, indicating a strategic alignment with government healthcare initiatives [1] - The company has pledged a significant investment of $100 billion over the next ten years, highlighting its commitment to research and development in the pharmaceutical sector [1]